Wisp Review: A Credible Platform Selling a Product That an FDA-Approved Pill Has Overtaken

What Is Wisp?

Wisp is a large direct-to-consumer telehealth platform best known for sexual and reproductive health — birth control, emergency contraception, UTI and STI care. It has extended into what it calls Weight Care, and the offering is narrower and more distinctive than most competitors.

Rather than a full menu of injectables, Wisp's flagship GLP-1 product is compounded sublingual semaglutide drops in a 15mL bottle at $225 per month. There is no compounded injectable line. Alongside it, Wisp sells Metabolic GLP Support Capsules at $54 per month, metformin for PCOS from $24, and a Weight Care Consult now priced at $99. Branded injectables — Wegovy, Zepbound and Saxenda — are referenced as requiring a consultation, with no price shown.

Scale is Wisp's strongest credential. The company states it is 'trusted by 1.8 million+ nationwide' and carries a 4.3 out of 5 company review rating. It advertises 100% online, board-certified medical providers, and states that if prescribed, treatment is sent same-day to your local pharmacy or delivered free and discreetly to your door.

One operational detail is worth knowing before you order: Wisp adds the lowest dosage of your chosen medication to your cart by default, with the provider reviewing and adjusting based on your medical history afterward. It is a product-first checkout flow with clinical review layered on.

Medications Offered & Pricing

Wisp's GLP-1 offering is narrow by design: compounded sublingual semaglutide is the only GLP-1 medication we found priced on its weight care pages. There is no compounded tirzepatide or injectable semaglutide line. Wisp does reference Wegovy in its weight care materials, and notes plainly that 'Wegovy and Wisp Inc. are separate and non-affiliated companies.' The Metabolic GLP Support Capsules at $54/month are a supplement rather than a prescription GLP-1 — do not confuse the two.

Brand-Name or Compounded?

This is the section that has changed most since we first reviewed Wisp, and it is the reason the rating has come down. Nothing here is an allegation against Wisp. It is a change in what else is available and in what the rules now permit.

Start with the alternative. On 18 December 2025 the FDA approved Wegovy tablets — oral semaglutide — under NDA 218316, for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight with at least one weight-related comorbidity, and for cardiovascular risk reduction. The recommended maintenance dose is 25 mg orally once daily, taken on an empty stomach in the morning with no more than four ounces of water and swallowed whole. The label states plainly: 'In patients without type 2 diabetes, the average semaglutide blood concentrations following administration of WEGOVY 25 mg tablets once daily or WEGOVY 2.4 mg injection once weekly were similar.' It also notes that in patients with type 2 diabetes those concentrations were lower than with the injection.

The significance for this review is direct. Wisp's flagship product exists to solve one problem — people who will not inject — and until recently a compounded preparation was the only needle-free semaglutide on offer. That is no longer true. There is now a needle-free semaglutide that the FDA has reviewed for safety and effectiveness, with published pharmacokinetics and outcome trials behind it. If you are choosing Wisp specifically to avoid needles, the first question to ask a clinician is whether Wegovy tablets are appropriate for you, not whether the drops work.

Next, the rules. The FDA declared the semaglutide shortage resolved in February 2025. Compounding these drugs was lawful at scale largely because the shortage listing permitted it, and when the shortage ended so did that permission: the enforcement discretion period for 503A state-licensed pharmacies and physicians compounding semaglutide injection products ended on 22 April 2025, and for 503B outsourcing facilities on 22 May 2025. Then, in a notice published on 1 May 2026 with comments closing 29 June 2026, the FDA proposed not to include semaglutide, tirzepatide or liraglutide on the 503B bulks list, having found no clinical need for outsourcing facilities to compound them from bulk substances. That proposal, if finalised, would close the 503B route for these drugs outside a shortage.

Two honest caveats, because the picture is genuinely nuanced and we do not want to imply more than we know. Those FDA orders are addressed to semaglutide *injection* products, and a sublingual drop is a different dosage form; compounders generally argue on that basis that a non-injectable preparation is not 'essentially a copy' of an approved drug. That argument is real and we are not in a position to adjudicate it. But it was always a stronger argument when no approved oral semaglutide existed, and an approved 25 mg tablet now does — which is precisely the kind of fact that bears on whether a compounded alternative meets a clinical need. Wisp does not name its compounding pharmacy partners, so we cannot tell you which facility makes this product or under which authority.

On the formulation itself, the original point still stands and is now sharper. Wisp describes its sublingual product as made with a base intended to improve absorption through the lining of the mouth. Semaglutide is a large peptide, and getting large peptides across the oral mucosa in a predictable dose is the hard problem — it is why the approved tablet requires an absorption enhancer, an empty stomach, a strict water limit and a 30-minute wait before anything else. None of the pivotal trials that established semaglutide's efficacy studied drops under the tongue. Wisp runs an FAQ entry titled 'How effective is the sublingual semaglutide?', which is more candour than most competitors offer and is also a signal that the question is unresolved. Wisp publishes no pharmacokinetic data for its drops that we could find, so there is no way for a reader to know what blood concentration a given dose produces.

One wording change is worth flagging. The disclaimer on the weight care page now reads: 'This product has not been evaluated by the FDA. The globally sourced medications offered are not intended to diagnose, treat, cure, or prevent any disease.' The phrase 'globally sourced' is new to us and is not explained on the page. The FDA has previously warned about compounded GLP-1 products made with active ingredient obtained from overseas suppliers, including salt forms of semaglutide that are not the same active ingredient as the approved drug. We are not asserting that applies here — we do not know where Wisp's ingredient comes from — but a customer is entitled to ask, and the page invites the question without answering it.

The baseline point has not changed: compounded semaglutide is not FDA-approved, is not reviewed by the FDA for safety or effectiveness, and is not a generic version of Ozempic or Wegovy. Wisp says so itself, and separates itself from the brand: 'Wegovy and Wisp Inc. are separate and non-affiliated companies.'

The Consultation Process

Eligibility

• •Wisp publishes eligibility requirements and asks you to read them before checkout, with a dedicated Treatment Eligibility section on the product page.
• •Board-certified medical providers make the clinical determination and adjust the default starting dose based on your medical history.
• •Wisp maintains a specific FAQ entry on which states can receive Weight Care Consults — state availability is limited, so check before ordering.
• •Wisp provides a BMI calculator and a related FAQ entry, though a specific published BMI threshold is not disclosed.
• •A named clinician, Dr. Shannon Chatham DO, is publicly associated with the Wisp Care Team.

Provider Involvement, Labs & Pharmacy

Shipping & Support Services

Free, discreet delivery to your door. Some Wisp products offer same-day local pharmacy pickup, though the compounded sublingual semaglutide is listed as available for delivery only. Wisp maintains FAQ entries on shipping method and whether medications require refrigeration — worth reading, since GLP-1 products are temperature-sensitive.

• •Access to the Wisp Care Team for ongoing questions
• •Free, discreet home delivery
• •Same-day pharmacy dispatch for eligible products
• •Anti-nausea support available alongside weight treatment
• •Extensive weight care FAQ covering effectiveness, safety, side effects and refrigeration
• •Optional Wisp+ membership at $30
• •15% off first order with an advertised welcome code

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Wisp May Be Best For

• •People who will not inject and specifically want a sublingual option
• •Existing Wisp customers already using the platform for other care
• •Patients who want a fast start — 24 to 72 hours from consult request to care
• •Anyone who values a large, established platform over a newer entrant
• •Patients who want anti-nausea support bundled into the same provider relationship

Limitations

• •The biggest limitation is no longer about Wisp at all — it is that the market moved. Wisp's sublingual drops were a sensible answer to a real problem when the only approved semaglutide came in a needle. The FDA approved Wegovy tablets in December 2025 with label pharmacokinetics comparable to the weekly injection in patients without type 2 diabetes. A compounded, unstudied preparation at $225 a month is a harder thing to justify against an approved 25 mg tablet, and any honest recommendation has to start by asking whether you are a candidate for the approved product.
• •The regulatory ground has shifted underneath compounded semaglutide generally. The shortage that made large-scale compounding permissible was declared resolved in February 2025, enforcement discretion ended in April and May 2025 for 503A and 503B respectively, and in May 2026 the FDA proposed removing semaglutide from the 503B bulks list entirely. Compounders argue that a sublingual drop is a distinct dosage form and therefore outside those orders, which are written for injection products. That may well be right — but it means the availability of this product depends on an unsettled legal argument, and a supply you may come to rely on could change.
• •The single-product catalog is the core constraint. If sublingual semaglutide does not suit you — because of absorption, tolerance, or because you need a dual-action GLP-1/GIP — Wisp has nowhere else to go. Providers like Midi Health and ShedRx offer sublingual options alongside injectables and dual-action formulations.
• •Sublingual dosing deserves genuine scrutiny. Wisp is upfront enough to run an FAQ entry titled 'How effective is the sublingual semaglutide?', which tells you the question is live. The clinical evidence base for semaglutide comes from injection trials.
• •Putting the product in your cart before a clinician has seen your history is a commerce-first flow. The review does happen, and the dose is adjusted afterward, but the sequencing is worth understanding.
• •State availability being answered only inside an FAQ, rather than shown before checkout, is a poor experience for a prescription product.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Wisp is a credible operator doing one narrow thing. With 1.8 million patients and a 4.3 rating, this is not a fly-by-night compounding storefront, and its weight care FAQ is genuinely more informative than most — it addresses effectiveness, safety, refrigeration and FDA status rather than dodging them. If you will not inject and want a sublingual GLP-1 from an established platform that can have care to you within 72 hours, the proposition is clear.

But the offering is thin for the price, and the price now competes against something it did not have to compete against before. $225 a month buys a single compounded sublingual product with no injectable alternative, no tirzepatide, and no dual-action option. Midi Health sells sublingual GLP-1 from $164 and sublingual dual-action from $209, priced by dose, from 503B-accredited pharmacies — with insurance-covered visits on top. On the specific thing Wisp does, competitors do more for less.

The larger problem is the approved tablet. In December 2025 the FDA approved Wegovy tablets at 25 mg once daily, and the label says blood concentrations are similar to the 2.4 mg weekly injection in people without type 2 diabetes. The entire premise of a compounded sublingual GLP-1 was that needle-free semaglutide did not otherwise exist. It does now, in a product the FDA has actually reviewed, with real outcome data behind it. Wisp cannot be blamed for a change in the market, but a reader deciding today has to weigh it, and the honest advice is to ask a clinician about the approved tablet first. Cost and insurance may still point back toward a compounded product for some people — that is a legitimate reason to choose one, and a different reason from the one Wisp's marketing leads with.

We would also want the sublingual efficacy question answered directly before starting. Wisp deserves genuine credit for raising it in its own FAQ rather than pretending it does not exist, but the fact that it needs an FAQ entry is the point: you are choosing a route of administration that the pivotal semaglutide trials did not study, from a product that publishes no pharmacokinetic data. Ask the provider what blood level the drops are expected to achieve and what evidence supports it. Go in with realistic expectations rather than assuming the drops perform like an injection.

Rated 3.4 out of 5, down from 4.0 at our previous review. The downgrade reflects the arrival of FDA-approved oral semaglutide and the tightening of the compounding rules, not any new concern about how Wisp operates. It remains a large, established platform that discloses more about compounding than most of its competitors, and if you have weighed the approved tablet and still want this, you are dealing with a serious company.